ArticleJournal of clinical medicine2024

Long-Term Efficacy and Safety of Guselkumab in Psoriasis Patients Who Failed Anti-IL17: A Two-Year Real-Life Study.

Matteo Megna et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.